Wire
Silexion Therapeutics Initiates Phase 2/3 Trial for Pancreatic Cancer Drug Candidate
Silexion Therapeutics (SLXN) said Wednesday it has initiated its phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer, adding that the clinical site is now cleared to commence patient screening.The trial will evaluate SIL204 in combination with standard-of-care chemotherapy. It is structured as an initial safety run-in group of 18 patients, followed by expansion into sites worldwide to obtain a randomized cohort of about 166 patients.Shares of the company fell over 21% in recent Wednesday trading.Price: $2.01, Change: $-0.54, Percent Change: -21.06%
$SLXN
